BC Innovations | Oct 25, 2019
Product Development

Lykera takes aim at aggressive cancers by targeting pre-metastatic niche

Lykera joins a growing wave of companies targeting the tumor stroma, but it is taking a different approach with a portfolio of first-in-class mAbs against S100 proteins implicated in driving metastases. Its lead programs are...
BC Innovations | Mar 29, 2017
Distillery Techniques

Biomarkers

TECHNOLOGY: Plasma markers A five-protein signature could help predict the risk of ischemic stroke, MI and death from cardiovascular events in atherosclerosis patients. In serum samples from 282 patients and 403 healthy volunteers, a protein...
BC Week In Review | Feb 16, 2015
Clinical News

APPY1 regulatory update

Venaxis said FDA issued a not substantially equivalent response to the company’s 501(k) application for APPY1 to aid emergency room clinicians in identifying patients at low risk for appendicitis in individuals ages 2-20 with abdominal...
BC Week In Review | Jan 19, 2015
Clinical News

APPY1 regulatory update

Venaxis submitted a response to FDA’s request for information related to its 510(k) application for APPY1 to aid emergency room clinicians in identifying patients at low risk for appendicitis in individuals ages 2-20 years with...
BC Week In Review | Jul 28, 2014
Clinical News

APPY1 regulatory update

Venaxis said FDA provided the company with questions and requested information as part of the agency’s review of a 510(k) application for APPY1 to identify patients that are at low risk for appendicitis. The company...
BC Innovations | Jun 26, 2014
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer S100 calcium binding protein A8 (S100A8; calgranulin A; MRP8); S100A9 (calgranulin B; MRP14) In vitro and mouse studies identified myeloid-derived suppressor cell (MDSC)-depleting peptides...
BC Innovations | May 29, 2014
Targets & Mechanisms

S100A9-clot not, bleed not

Although the new generation of antithrombotic drugs provides marked improvements over warfarin, they all still carry bleeding risk. S100 calcium binding protein A9 could represent a new target that, when blocked, prevents thrombosis without increasing...
BC Week In Review | Apr 7, 2014
Clinical News

APPY1 regulatory update

Venaxis submitted a 510(k) application to FDA for APPY1 to identify patients that are at low risk for appendicitis. The company is also seeking concurrent de novo classification of the test by FDA. FDA's de...
BC Week In Review | Mar 17, 2014
Clinical News

APPY1: Pivotal trial data

Top-line data from the U.S. pivotal CP-12 trial in 1,887 patients showed that Venaxis' APPY1 Test had an NPV of 97.3% for identifying patients at low risk for appendicitis. APPY1 Test also had 96.9% sensitivity...
BC Extra | Mar 13, 2014
Clinical News

Venaxis reports pivotal data for appendicitis diagnostic

Venaxis Inc. (NASDAQ:APPY) said its APPY1 Test had a negative predictive value (NPV) of 97.3% for identifying patients at low risk for appendicitis in the pivotal U.S. CP-12 trial. The test also had 96.9% sensitivity...
Items per page:
1 - 10 of 29